{"id":"https://openalex.org/W7223089891","doi":"https://doi.org/10.1016/j.htct.2026.107507","title":"HEALTH-RELATED QUALITY OF LIFE AND HEALTH UTILITY AMONG BRAZILIAN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA RECEIVING TYROSINE KINASE INHIBITORS: REAL-WORLD EVIDENCE FROM BRAZIL","display_name":"HEALTH-RELATED QUALITY OF LIFE AND HEALTH UTILITY AMONG BRAZILIAN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA RECEIVING TYROSINE KINASE INHIBITORS: REAL-WORLD EVIDENCE FROM BRAZIL","publication_year":2026,"publication_date":"2026-10-01","ids":{"openalex":"https://openalex.org/W7223089891","doi":"https://doi.org/10.1016/j.htct.2026.107507"},"language":"en","primary_location":{"id":"doi:10.1016/j.htct.2026.107507","doi":"https://doi.org/10.1016/j.htct.2026.107507","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.htct.2026.107507","pdf_url":"https://www.sciencedirect.com/science/article/pii/S253113792601254X/pdf","source":{"id":"https://openalex.org/S2898598332","display_name":"Hematology Transfusion and Cell Therapy","issn_l":"2531-1379","issn":["2531-1379","2531-1387"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","ki-jl-1","poland-20","russia-white-list-3","scielo"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematology, Transfusion and Cell Therapy","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://www.sciencedirect.com/science/article/pii/S253113792601254X/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5013700840","display_name":"Diego Kashiura","orcid":"https://orcid.org/0000-0001-7275-6358","observed_orcids":["https://orcid.org/0000-0001-7275-6358"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Diego KASHIURA","raw_affiliation_strings":["Novartis Bioci\u00eancias S.A., S\u00e3o Paulo, SP, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Bioci\u00eancias S.A., S\u00e3o Paulo, SP, Brazil","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159184256","display_name":"Diogo NOIN DE OLIVEIRA","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Diogo NOIN DE OLIVEIRA","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159183483","display_name":"Ana Beatriz MACHADO DE ALMEIDA","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ana Beatriz MACHADO DE ALMEIDA","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076940406","display_name":"Alessandro Bigoni","orcid":"https://orcid.org/0000-0002-2483-3299","observed_orcids":["https://orcid.org/0000-0002-2483-3299"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alessandro BIGONI","raw_affiliation_strings":["Novartis Bioci\u00eancias S.A., S\u00e3o Paulo, SP, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Bioci\u00eancias S.A., S\u00e3o Paulo, SP, Brazil","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159176199","display_name":"Priscila RAUPP DA ROSA","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Priscila RAUPP DA ROSA","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5146473289","display_name":"Leonardo Hiago Gattas","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Leonardo Hiago GATTAS","raw_affiliation_strings":["Novartis Bioci\u00eancias S.A., S\u00e3o Paulo, SP, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Bioci\u00eancias S.A., S\u00e3o Paulo, SP, Brazil","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159164430","display_name":"Michelly Yumi TUBONE DONI","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michelly Yumi TUBONE DONI","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159208190","display_name":"Jamile COUTRIM DALRI","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jamile COUTRIM DALRI","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159221328","display_name":"Nina MELO","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nina MELO","raw_affiliation_strings":["Associa\u00e7\u00e3o Brasileira de C\u00e2ncer do Sangue (Abrale), S\u00e3o Paulo, SP, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Associa\u00e7\u00e3o Brasileira de C\u00e2ncer do Sangue (Abrale), S\u00e3o Paulo, SP, Brazil","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159214314","display_name":"Janaina ROSENBURG GIOSEFF","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Janaina ROSENBURG GIOSEFF","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159220281","display_name":"Catherine Moura da Fonseca PINTO","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Catherine MOURA DA FONSECA PINTO","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5159200552","display_name":"Lucas Kaoru KOBO FERREIRA","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lucas Kaoru KOBO FERREIRA","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":0,"currency":"USD","value_usd":0},"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.82639479,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"48","issue":null,"first_page":"107507","last_page":"107507"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9409000277519226,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9409000277519226,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.05209999904036522,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10178","display_name":"Cancer survivorship and care","score":0.0027000000700354576,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chronic-phase-cml","display_name":"chronic phase CML","score":0.9279999732971191},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.9929999709129333},{"id":"https://openalex.org/keywords/health-related-quality-of-life","display_name":"health-related quality of life","score":0.9990000128746033},{"id":"https://openalex.org/keywords/health-utility","display_name":"health utility","score":0.9700000286102295},{"id":"https://openalex.org/keywords/eq-5d-3l","display_name":"EQ-5D-3L","score":0.9739999771118164},{"id":"https://openalex.org/keywords/eq-vas","display_name":"EQ-VAS","score":0.8080000281333923},{"id":"https://openalex.org/keywords/brazilian-patients","display_name":"Brazilian patients","score":0.6660000085830688},{"id":"https://openalex.org/keywords/comorbidity-burden","display_name":"comorbidity burden","score":0.8270000219345093},{"id":"https://openalex.org/keywords/treatment-lines","display_name":"treatment lines","score":0.8320000171661377},{"id":"https://openalex.org/keywords/patient-reported-outcomes","display_name":"patient-reported outcomes","score":0.9350000023841858},{"id":"https://openalex.org/keywords/real-world-evidence","display_name":"real-world evidence","score":0.6830000281333923},{"id":"https://openalex.org/keywords/brazil","display_name":"Brazil","score":0.3199999928474426},{"id":"https://openalex.org/keywords/health-insurance-coverage","display_name":"health insurance coverage","score":0.30300000309944153},{"id":"https://openalex.org/keywords/socioeconomic-status","display_name":"socioeconomic status","score":0.34599998593330383}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9610000252723694},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.8108000159263611},{"id":"https://openalex.org/C2779951463","wikidata":"https://www.wikidata.org/wiki/Q7268788","display_name":"Quality of life (healthcare)","level":2,"score":0.6399000287055969},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.5583000183105469},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5579000115394592},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5454000234603882},{"id":"https://openalex.org/C3019006561","wikidata":"https://www.wikidata.org/wiki/Q7268788","display_name":"Health related quality of life","level":3,"score":0.40860000252723694},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.37770000100135803},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.3488999903202057},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.33379998803138733},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3151000142097473},{"id":"https://openalex.org/C2779282312","wikidata":"https://www.wikidata.org/wiki/Q1956561","display_name":"Myeloid","level":2,"score":0.30000001192092896}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1016/j.htct.2026.107507","doi":"https://doi.org/10.1016/j.htct.2026.107507","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.htct.2026.107507","pdf_url":"https://www.sciencedirect.com/science/article/pii/S253113792601254X/pdf","source":{"id":"https://openalex.org/S2898598332","display_name":"Hematology Transfusion and Cell Therapy","issn_l":"2531-1379","issn":["2531-1379","2531-1387"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","ki-jl-1","poland-20","russia-white-list-3","scielo"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematology, Transfusion and Cell Therapy","raw_type":"journal-article"},{"id":"pmh:oai:doaj.org/article:3a8b95a0e8954e698bd3471011257cb3","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/3a8b95a0e8954e698bd3471011257cb3","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Hematology, Transfusion and Cell Therapy, Vol 48, Iss , Pp 107507- (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1016/j.htct.2026.107507","doi":"https://doi.org/10.1016/j.htct.2026.107507","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.htct.2026.107507","pdf_url":"https://www.sciencedirect.com/science/article/pii/S253113792601254X/pdf","source":{"id":"https://openalex.org/S2898598332","display_name":"Hematology Transfusion and Cell Therapy","issn_l":"2531-1379","issn":["2531-1379","2531-1387"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","ki-jl-1","poland-20","russia-white-list-3","scielo"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematology, Transfusion and Cell Therapy","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7223089891.pdf","grobid_xml":"https://content.openalex.org/works/W7223089891.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3194725997","https://openalex.org/W2062213849","https://openalex.org/W3135649738","https://openalex.org/W4404707511","https://openalex.org/W4312329492","https://openalex.org/W4229331934","https://openalex.org/W2584630593","https://openalex.org/W1970476017","https://openalex.org/W2136202822","https://openalex.org/W3205645533"],"abstract_inverted_index":{"Background":[0],"Advances":[1],"in":[2,170,196,201,235,251,457],"tyrosine":[3],"kinase":[4],"inhibitor":[5],"(TKI)":[6],"therapy":[7],"have":[8],"substantially":[9],"improved":[10],"survival":[11],"outcomes":[12],"for":[13,89,184],"patients":[14,21,48,188,273,297,351,378,422,440],"with":[15,49,81,189,363,367,387,397,423,449,459],"chronic":[16],"myeloid":[17],"leukemia":[18,473],"(CML).":[19],"As":[20],"increasingly":[22],"achieve":[23],"long-term":[24],"disease":[25],"control,":[26],"health-related":[27],"quality":[28],"of":[29,296,372,410,415,466],"life":[30],"(HRQoL)":[31],"has":[32],"become":[33],"an":[34,86,121,171,202],"important":[35],"treatment":[36,59,212,269,445],"outcome.":[37],"Aim":[38],"To":[39],"characterize":[40],"HRQoL":[41,124,237,360,416,430,458],"and":[42,54,61,68,114,134,232,255,285,305,322,345,355,390,417,446],"health":[43,266,418],"utility":[44,142,315,334,370,419,435],"scores":[45,143,335,371,436],"among":[46,350,377,385,395,420,439,447],"Brazilian":[47,76,99,148,421],"chronic-phase":[50,83,424],"CML":[51,84,191,425],"receiving":[52,85,275,352,426,441],"TKI":[53,88,211,278,427],"to":[55,163],"explore":[56],"associations":[57],"between":[58],"line":[60],"comorbidity":[62,365,452,461],"burden":[63,462],"on":[64,469],"patient-reported":[65],"outcomes.":[66],"Materials":[67],"methods":[69],"This":[70,406],"prospective,":[71],"cross-sectional,":[72],"non-interventional":[73],"study":[74,407],"enrolled":[75],"adults":[77],"(\u2265":[78,291],"18":[79,219,221],"years)":[80],"confirmed":[82],"approved":[87],"at":[90],"least":[91],"1":[92],"month.":[93],"Participants":[94,239],"were":[95,144,175,182,233,240,274,336,437],"recruited":[96],"through":[97,120,264],"the":[98,128,135,147,230,236,323,411,464],"Blood":[100],"Cancer":[101],"Association":[102],"(ABRALE).":[103],"Following":[104],"ethics":[105],"committee":[106],"approval,":[107],"eligible":[108,183],"participants":[109],"provided":[110],"electronic":[111,122],"informed":[112,165],"consent":[113,166],"completed":[115,229],"structured":[116],"self-administered":[117],"digital":[118],"questionnaires":[119],"platform.":[123],"was":[125,317,327,431],"assessed":[126],"using":[127,146],"EuroQol":[129],"5-Dimension":[130],"3-Level":[131],"questionnaire":[132],"(EQ-5D-3L)":[133],"EQ":[136],"Visual":[137],"Analogue":[138],"Scale":[139],"(EQ-VAS).":[140],"EQ-5D-3L":[141,231,314,333,369],"derived":[145],"time":[149],"trade-off":[150],"(TTO)":[151],"value":[152],"set":[153],"developed":[154],"by":[155],"Santos":[156],"et":[157],"al.":[158],"Patients":[159],"unwilling":[160],"or":[161,167,197,216,289,309,443],"unable":[162],"provide":[164],"currently":[168],"participating":[169],"interventional":[172,203],"clinical":[173,204],"trial":[174,205],"excluded.":[176],"Results":[177],"Of":[178,226],"216":[179],"respondents,":[180],"137":[181],"inclusion":[185],"after":[186],"excluding":[187],"non\u2013chronic-phase":[190],"(n":[192,206,213,223],"=":[193,207,214,224],"4),":[194],"participation":[195,200],"uncertainty":[198],"regarding":[199],"22),":[208],"no":[209,299],"current":[210],"46),":[215],"age":[217],"<":[218,403],"lt;":[220],"years":[222,246],"7).":[225],"these,":[227],"99":[228],"included":[234],"analysis.":[238],"predominantly":[241],"female":[242],"(61.6%),":[243],"aged":[244],"40\u201359":[245],"(46.5%),":[247],"White":[248],"(65.7%),":[249],"residing":[250],"Southeastern":[252],"Brazil":[253],"(52.5%),":[254],"had":[256],"a":[257,450],"university":[258],"degree":[259],"(41.4%);":[260],"52.5%":[261],"received":[262],"care":[263],"private":[265],"insurance.":[267],"Regarding":[268],"history,":[270],"40":[271],"(40.4%)":[272],"first-line":[276],"(1L)":[277],"therapy,":[279,284,358],"35":[280],"(35.4%)":[281],"second-line":[282],"(2L)":[283],"24":[286],"(24.2%)":[287],"third-line":[288,442],"later":[290,444],"3L)":[292],"therapy.":[293,428],"Overall,":[294,429],"45.5%":[295],"reported":[298,302,307],"comorbidities,":[300,380],"32.3%":[301],"one":[303,388,409],"comorbidity,":[304,389],"22.2%":[306],"two":[308],"more":[310],"comorbidities.":[311],"The":[312,454],"mean":[313,324,368],"score":[316,326],"0.748":[318],"(95%":[319,329,338,342,347,374,382,392],"CI,":[320,330,375,383,393],"0.716\u20130.780),":[321],"EQ-VAS":[325],"73.5":[328],"69.9\u201377.0).":[331],"Mean":[332],"0.766":[337],"CI:":[339,343,348],"0.720\u20130.812),":[340],"0.762":[341],"0.715\u20130.810),":[344],"0.696":[346],"0.615\u20130.777)":[349],"1L,":[353],"2L,":[354],"\u2265":[356,398],"3L":[357],"respectively.":[359],"decreased":[361],"progressively":[362],"increasing":[364,460],"burden,":[366],"0.826":[373],"0.784\u20130.869)":[376],"without":[379],"0.706":[381],"0.659\u20130.753)":[384],"those":[386,396,448],"0.648":[391],"0.582\u20130.714)":[394],"2":[399],"comorbidities":[400],"(Kruskal\u2013Wallis":[401],"p":[402],"0.001).":[404],"Conclusion":[405],"provides":[408],"first":[412],"real-world":[413],"assessments":[414],"favorable;":[432],"however,":[433],"lower":[434],"observed":[438],"higher":[451],"burden.":[453],"progressive":[455],"decline":[456],"highlights":[463],"impact":[465],"comorbid":[467],"conditions":[468],"patient":[470],"well-being":[471],"beyond":[472],"control":[474],"alone.":[475]},"counts_by_year":[],"updated_date":"2026-11-08T12:12:28.789561","created_date":"2026-10-22T00:00:00"}